A Phase IB Clinical Study of TBio-4101 (Autologous Selected and Expanded Tumor-Infiltrating Lymphocytes [TIL]) and Pembrolizumab With or Without Chemotherapy in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Cancer (HNSCC)

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 20 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pembrolizumab (Primary) ; TIDAL-01 (Primary) ; Aldesleukin; Carboplatin; Cisplatin; Cyclophosphamide; Fludarabine
Indications Head and neck cancer; Squamous cell cancer
Focus Adverse reactions

Most Recent Events

13 Feb 2025 Planned End Date changed from 1 May 2026 to 1 Aug 2026.
13 Feb 2025 Planned primary completion date changed from 1 May 2026 to 1 Aug 2026.
04 Feb 2025 According to a Turnstone Biologics media release, the company has made the determination to discontinue all clinical studies evaluating TIDAL-01 and halt further development of the program.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight